Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 In vitro activities of azithromycin (CP 62,993), clarithromycin (A-56268; TE-031), erythromycin, roxithromycin, and clindamycin.

Literature DB >> 2840016

In vitro activities of azithromycin (CP 62,993), clarithromycin (A-56268; TE-031), erythromycin, roxithromycin, and clindamycin.

Abstract

The in vitro activity of azithromycin (CP 62,993 or XZ-450) against Haemophilus influenzae was greater than that of three other macrolides. However, azithromycin was four- to eightfold less active than erythromycin against the gram-positive cocci and against Listeria monocytogenes. Erythromycin and azithromycin were similar in their activity against Legionella pneumophila, Neisseria gonorrhoeae, Neisseria meningitidis, and Branhamella catarrhalis.

Entities: Chemical Species

Mesh：

Substances：

Year: 1988 PMID： 2840016 PMCID： PMC172265 DOI： 10.1128/AAC.32.5.752

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

8 in total

1. In-vitro activity of erythromycin, roxithromycin and CP 62993 against common paediatric pathogens.

Authors: S C Aronoff; C Laurent; M R Jacobs
Journal: J Antimicrob Chemother Date: 1987-02 Impact factor: 5.790

2. The antimicrobial activity of A-56268 (TE-031) and roxithromycin (RU965) against Legionella using broth microdilution method.

Authors: R N Jones; A L Barry
Journal: J Antimicrob Chemother Date: 1987-06 Impact factor: 5.790

3. In vitro activity of a new macrolide, A-56268, compared with that of roxithromycin, erythromycin, and clindamycin.

Authors: A L Barry; C Thornsberry; R N Jones
Journal: Antimicrob Agents Chemother Date: 1987-02 Impact factor: 5.191

4. Disk diffusion and disk elution tests with A-56268 and erythromycin.

Authors: A L Barry; R N Jones; C Thornsberry
Journal: Eur J Clin Microbiol Date: 1987-02 Impact factor: 3.267

5. Erythromycin: a microbial and clinical perspective after 30 years of clinical use (1).

Authors: J A Washington; W R Wilson
Journal: Mayo Clin Proc Date: 1985-03 Impact factor: 7.616

6. In vitro evaluation of three new macrolide antimicrobial agents, RU28965, RU29065, and RU29702, and comparisons with other orally administered drugs.

Authors: R N Jones; A L Barry; C Thornsberry
Journal: Antimicrob Agents Chemother Date: 1983-08 Impact factor: 5.191

7. Effect of several components of anaerobic incubation on antibiotic susceptibility test results.

Authors: J E Rosenblatt; F Schoenknecht
Journal: Antimicrob Agents Chemother Date: 1972-05 Impact factor: 5.191

8. In vitro and in vivo evaluation of A-56268 (TE-031), a new macrolide.

Authors: P B Fernandes; R Bailer; R Swanson; C W Hanson; E McDonald; N Ramer; D Hardy; N Shipkowitz; R R Bower; E Gade
Journal: Antimicrob Agents Chemother Date: 1986-12 Impact factor: 5.191

8 in total

28 in total

1. Antimicrobial activities and postantibiotic effects of clarithromycin, 14-hydroxy-clarithromycin, and azithromycin in epithelial cell lining fluid against clinical isolates of haemophilus influenzae and Streptococcus pneumoniae.

Authors: K L Bergman; K M Olsen; T E Peddicord; P D Fey; M E Rupp
Journal: Antimicrob Agents Chemother Date: 1999-05 Impact factor: 5.191

2. Concentration of azithromycin in human prostatic tissue.

Authors: G Foulds; P Madsen; C Cox; R Shepard; R Johnson
Journal: Eur J Clin Microbiol Infect Dis Date: 1991-10 Impact factor: 3.267

3. Safety, toleration, and pharmacokinetics of intravenous azithromycin.

Authors: D R Luke; G Foulds; S F Cohen; B Levy
Journal: Antimicrob Agents Chemother Date: 1996-11 Impact factor: 5.191

4. Quality control parameters and interpretive criteria for in vitro susceptibility tests with the macrolide azithromycin. Collaborative Antimicrobial Susceptibility Testing Group.

Authors: A L Barry; C Thornsberry; T L Gavan
Journal: Eur J Clin Microbiol Infect Dis Date: 1989-06 Impact factor: 3.267

5. Effects of environmental factors on the in vitro potency of azithromycin.

Authors: J A Retsema; L A Brennan; A E Girard
Journal: Eur J Clin Microbiol Infect Dis Date: 1991-10 Impact factor: 3.267

6. Influence of the test medium on azithromycin and erythromycin regression statistics.

Authors: A L Barry; P C Fuchs
Journal: Eur J Clin Microbiol Infect Dis Date: 1991-10 Impact factor: 3.267

7. In vitro and in vivo activities of macrolides against Mycobacterium leprae.

Authors: S G Franzblau; R C Hastings
Journal: Antimicrob Agents Chemother Date: 1988-12 Impact factor: 5.191

8. Effect of CO2 on susceptibilities of anaerobes to erythromycin, azithromycin, clarithromycin, and roxithromycin.

Authors: S K Spangler; M R Jacobs; P C Appelbaum
Journal: Antimicrob Agents Chemother Date: 1994-02 Impact factor: 5.191

9. A randomized trial of roxithromycin in patients with acute leukemia and bone marrow transplant recipients receiving fluoroquinolone prophylaxis.

Authors: W V Kern; B Hay; P Kern; R Marre; R Arnold
Journal: Antimicrob Agents Chemother Date: 1994-03 Impact factor: 5.191

10. Renal tubular enzyme effects of clarithromycin in comparison with gentamicin and placebo in volunteers.

Authors: M C Chapelsky; D E Nix; J C Cavanaugh; J H Wilton; A Norman; J J Schentag
Journal: Drug Saf Date: 1992 Jul-Aug Impact factor: 5.606